CALIFORNIA HEART CENTER FOUNDATION: Form 990, tax year 2011

View the entire original 990 at ProPublica ↗

Organization
CALIFORNIA HEART CENTER FOUNDATION (EIN 95-4772979)
Tax period
2011-01-01 to 2011-12-31
Filed
2012-11-13
IRS object ID
201203189349304790
Schema version
2011v1.2
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Timestamp2012-11-13T18:40:41-06:00Timestamp
Tax Period End Date2011-12-31TaxPeriodEndDate

Preparer Firm PreparerFirm

FieldValueIRS element (for citing)
EIN346565596EIN

Preparer Firm Business Name PreparerFirmBusinessName

FieldValueIRS element (for citing)
Business Name Line1ERNST & YOUNG US LLPBusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

FieldValueIRS element (for citing)
Address Line118111 VON KARMAN AVENUE SUITE 1000AddressLine1
CityIRVINECity
StateCAState
ZIP Code92612ZIPCode
FieldValueIRS element (for citing)
Return Type990ReturnType
Tax Period Begin Date2011-01-01TaxPeriodBeginDate

Filer Filer

FieldValueIRS element (for citing)
EIN954772979EIN

Name Name

FieldValueIRS element (for citing)
Business Name Line1CALIFORNIA HEART CENTER FOUNDATIONBusinessNameLine1
FieldValueIRS element (for citing)
Name ControlCALINameControl
Phone3102488327Phone

US Address USAddress

FieldValueIRS element (for citing)
Address Line18536 WILSHIRE BOULEVARD 3RD FLOORAddressLine1
CityBEVERLY HILLSCity
StateCAState
ZIP Code90211ZIPCode

Officer Officer

FieldValueIRS element (for citing)
NameTHOMAS D GORDONName
TitleCFOTitle
Phone3102488327Phone
Date Signed2012-11-13DateSigned
Authorize Third Party1AuthorizeThirdParty

Preparer Preparer

FieldValueIRS element (for citing)
NameKARA ADAMSName
PTINP00023315PTIN
Phone9497942300Phone
FieldValueIRS element (for citing)
Tax Year2011TaxYear
Build TS2016-02-24 21:20:13ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Name Of Principal Officer PersonERIC N MARTONNameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

FieldValueIRS element (for citing)
Address Line18536 WILSHIRE BOULEVARD 3RD FLOORAddressLine1
CityBEVERLY HILLSCity
StateCAState
ZIP Code90211ZIPCode
FieldValueIRS element (for citing)
Gross Receipts1329412GrossReceipts
Group Return For Affiliates0GroupReturnForAffiliates
Organization501c3XOrganization501c3
Web SiteWWW.CALIFORNIAHEARTCENTER.ORGWebSite
Type Of Organization CorporationXTypeOfOrganizationCorporation
Year Formation2000YearFormation
State Legal DomicileCAStateLegalDomicile
Activity Or Mission DescriptionPROMOTE & DEVELOP EDUCATIONAL & SCIENTIFIC RESEARCH TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE.ActivityOrMissionDescription
Nbr Voting Members Governing Body18NbrVotingMembersGoverningBody
Nbr Independent Voting Members13NbrIndependentVotingMembers
Total Nbr Employees0TotalNbrEmployees
Total Nbr Volunteers19TotalNbrVolunteers
Total Gross UBI0TotalGrossUBI
Net Unrelated Business Txbl Income0NetUnrelatedBusinessTxblIncome
Contributions Grants Prior Year2355777ContributionsGrantsPriorYear
Contributions Grants Current Year1280861ContributionsGrantsCurrentYear
Program Service Revenue Prior Year27000ProgramServiceRevenuePriorYear
Program Service Revenue CY29520ProgramServiceRevenueCY
Investment Income Prior Year12029InvestmentIncomePriorYear
Investment Income Current Year19031InvestmentIncomeCurrentYear
Other Revenue Prior Year2310OtherRevenuePriorYear
Other Revenue Current Year0OtherRevenueCurrentYear
Total Revenue Prior Year2397116TotalRevenuePriorYear
Total Revenue Current Year1329412TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year0GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY0GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year0BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY0BenefitsPaidToMembersCY
Salaries Etc Prior Year1243501SalariesEtcPriorYear
Salaries Etc Current Year1113280SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year0TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY0TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year0TotalFundrsngExpCurrentYear
Other Expense Prior Year673594OtherExpensePriorYear
Other Expenses Current Year458228OtherExpensesCurrentYear
Total Expenses Prior Year1917095TotalExpensesPriorYear
Total Expenses Current Year1571508TotalExpensesCurrentYear
Revenues Less Expenses Prior Year480021RevenuesLessExpensesPriorYear
Revenues Less Expenses CY-242096RevenuesLessExpensesCY
Total Assets BOY1223690TotalAssetsBOY
Total Assets EOY966262TotalAssetsEOY
Total Liabilities BOY77487TotalLiabilitiesBOY
Total Liabilities EOY81870TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY1146203NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY884392NetAssetsOrFundBalancesEOY
Info In Schedule O Part IIIXInfoInScheduleOPartIII
Mission DescriptionTHE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES.MissionDescription
Significant New Program Services0SignificantNewProgramServices
Significant Change0SignificantChange
Expense1103728Expense
Revenue29520Revenue
DescriptionTHE MISSION OF THE CALIFORNIA HEART CENTER FOUNDATION IS TO ADVANCE THE FIELD OF CARDIOVASCULAR MEDICINE THROUGH CLINICAL RESEARCH INITIATIVES AND EDUCATIONAL INITIATIVES. OUR EFFORTS INCLUDE THE PURSUIT OF COLLABORATIVE RESEARCH PROJECTS WHICH PROMOTE A DEEPER UNDERSTANDING OF DISEASE PROGRESSION AND TEST THE EFFICACY OF NEW STRATEGIES FOR DIAGNOSIS AND TREATMENT. AREAS OF RESEARCH CURRENTLY BEING PURSUED INCLUDE NON-INVASIVE METHODS TO DETECT ORGAN REJECTION, NOVEL IMMUNOSUPPRESSIVE AGENTS, IMMUNE MONITORING STRATEGIES, LONG-TERM COMPLICATIONS SUCH AS CARDIAC ALLOGRAFT VASCULOPATHY, (CONTINUED ON SCHEDULE O)(CONTINUATION FROM FORM 990, PAGE 2)NOVEL METHODS FOR ORGAN PROCUREMENT AND PRESERVATION, NEW MECHANICAL CIRCULATORY SUPPORT DEVICES AND PULMONARY HYPERTENSION. THE ORGANIZATION ALSO SUPPORTS IMPORTANT SCIENTIFIC SYMPOSIA, WHICH ALLOW FOR THE EXCHANGE OF IDEAS AMONG LEADERS IN THE FIELD AND PROVIDE A FORUM FOR EXPERTS TO SHARE THEIR EXPERIENCE AND KNOWLEDGE WITH OTHER PRACTITIONERS. THE ORGANIZATION RESOURCES ARE ALSO LEVERAGED TO SUPPORT A SUMMER RESEARCH INTERNSHIP PROGRAM FOR UNDERGRADUATE STUDENTS WITH AN INTEREST IN MEDICINE AND/OR ACADEMIC RESEARCH. FOLLOWING IS A SUMMARY OF PROJECTS AND PROGRAMS IMPLEMENTED IN 2011: CONSENSUS CONFERENCE: CRUCIAL CONVERSATIONS IN THORACIC TRANSPLANT NURSING: SPONSORED JOINTLY BY THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION AND THE CEDARS-SINAI HEART INSTITUTE IN COOPERATION WITH THE ISHLT SCIENTIFIC COUNCIL FOR NURSING, HEALTH SCIENCE AND ALLIED HEALTH, "CRUCIAL CONVERSATIONS IN THORACIC TRANSPLANT NURSING" WAS HELD ON APRIL 12TH, 2011 IN SAN DIEGO, CALIFORNIA. THE MEETING WAS DESIGNED TO PROVIDE A FORUM FOR TRANSPLANT NURSES AND OTHER ALLIED HEALTH PROFESSIONALS TO DISCUSS THE EVOLUTION OF NURSING IN THIS SPECIALIZED AREA OF MEDICINE AND THE FUTURE ROLE OF TRANSPLANT NURSE PROFESSIONALS IN CREATING STANDARDS FOR PATIENT CARE AND EDUCATION. THE CONFERENCE WAS ATTENDED BY 71 TRANSPLANT NURSE PROFESSIONALS FROM 14 COUNTRIES. WITH JON KOBASHIGAWA SERVING AS A CONFERENCE ADVISOR AND CHAIR OF THE PLANNING COMMITTEE, THE CONFERENCE WAS EXTREMELY WELL RECEIVED. A REPORT ON THE CONSENSUS CONFERENCE IS EXPECTED TO BE PUBLISHED LATER THIS YEAR, WITH THE HOPE OF BEING A FIRST STEP IN ESTABLISHING TRANSPLANT NURSING CRITERIA AND COMPETENCIES.OPTIMAL CARE AND NEW THERAPIES FOR ADVANCED HEART DISEASE: DESIGNED AS AN EDUCATIONAL SERIES FOR COMMUNITY PHYSICIANS, COURSES WERE OFFERED ON MAY 21, 2011 IN BAKERSFIELD, CALIFORNIA ON SEPTEMBER 17TH, 2011 IN NEWPORT BEACH, CALIFORNIA AND ON OCTOBER 22ND, 2011 IN LAS VEGAS, NEVADA. THESE ONE-DAY COURSES FEATURED EXPERT PRESENTERS ON TOPICS RELATED TO THE DIAGNOSIS, TREATMENT AND MANAGEMENT OF ADVANCED HEART DISEASE, FOCUSING ON CORE COMPETENCIES OF ADVANCED HEART FAILURE, MECHANICAL CIRCULATORY SUPPORT, SURGICAL INTERVENTIONS AND TRANSPLANT CARDIOLOGY. ATTENDED BY COMMUNITY CARDIOLOGISTS, INTERNISTS, FAMILY PRACTICE PHYSICIANS AND ALLIED HEALTH STAFF, THE COURSE INCLUDED A COMBINATION OF DIDACTIC LECTURES AND CASE BASED PRESENTATIONS WITH EMPHASIS ON GUIDELINES, KNOWLEDGE, AND PRACTICE MANAGEMENT.SUMMER RESEARCH INTERNSHIPS: UNDER THE SUPERVISION AND MENTORSHIP OF JON KOBASHIGAWA, SUMMER HEART TRANSPLANT RESEARCH INTERNSHIPS WERE OFFERED TO EIGHT STUDENTS IN MAY 2011. THESE INTERNSHIPS PROVIDE STUDENTS AT ALL LEVELS OF TRAINING AN OPPORTUNITY TO LEARN THE CLINICAL RESEARCH PROCESS, INCLUDING MEDICAL LITERATURE REVIEW, STUDY DESIGN, CHART REVIEW/DATA COLLECTION, DATA ANALYSIS, AND ABSTRACT DEVELOPMENT AND SUBMISSION. COMPLETED ABSTRACTS WERE SUBMITTED AND ACCEPTED TO THE AMERICAN FEDERATION OF MEDICAL RESEARCH, A FORUM FOR JUNIOR INVESTIGATORS. THIS YEAR'S GROUP INCLUDES A FIRST YEAR MEDICAL STUDENT FROM THE UNIVERSITY OF NEVADA LAS VEGAS, AND UNDERGRADUATE STUDENTS FROM AMHERST COLLEGE, BROWN UNIVERSITY, WASHINGTON UNIVERSITY, AND THE UNIVERSITY OF CALIFORNIA LOS ANGELES.HEART TRANSPLANT JOURNAL CLUB: IN 2011, THE FOUNDATION BEGAN COORDINATING AND SPONSORING MONTHLY MEETINGS FOR PHYSICIANS, FELLOWS, RESIDENTS AND STUDENTS TO REVIEW AND DISCUSS JOURNAL ARTICLES RELATED TO TRANSPLANTATION. HELD ON THE FIRST TUESDAY OF EACH MONTH, JOURNAL CLUBS ARE MODERATED BY DR. JIGNESH PATEL.PATIENT EDUCATION SERIES: PATIENT LECTURES BY DR. JON KOBASHIGAWA WERE ORGANIZED IN MAY AND DECEMBER 2011. COVERING "CURRENT TRENDS IN HEART TRANSPLANTATION", THE PROGRAM PROVIDED BOTH PRE AND POST-TRANSPLANT PATIENTS WITH AN OVERVIEW OF ADVANCES IN THE FIELD OF HEART TRANSPLANTATION AND INCLUDED AN EXTENSIVE QUESTION AND ANSWER SESSION. RESEARCH STUDIES (ONGOING AND NEWLY INITIATED):STUDY TITLE: EARLY INVASIVE MONITORING ATTENUATION THROUGH GENE EXPRESSION (EIMAGE)SPONSOR: EXPRESSION DIAGNOSTICS INC.PROJECT SUMMARY: THE PURPOSE OF THIS STUDY IS TO COMPARE THE SAFETY AND EFFECTIVENESS OF GENE EXPRESSION BLOOD TESTS TO THE COMMONLY USED METHOD OF HEART BIOPSIES FOR MONITORING ACUTE REJECTION IN PATIENTS WHO HAVE HAD A HEART TRANSPLANT. REJECTION IS PART OF THE BODY'S NATURAL DEFENSE AGAINST DISEASE AND IT IS A NORMAL RESPONSE BY THE BODY'S IMMUNE SYSTEM TO A TRANSPLANTED ORGAN. HISTORICALLY, THE STANDARD METHOD TO DETERMINE REJECTION HAS BEEN THROUGH ROUTINE HEART BIOPSIES. HOWEVER, A HEART BIOPSY IS AN INVASIVE PROCEDURE THAT REQUIRES PUTTING A SMALL TUBE THROUGH THE NECK OR GROIN INTO THE HEART; A VERY SMALL PIECE OF THE HEART TISSUE IS REMOVED AND EXAMINED FOR SIGNS OF REJECTION. BECAUSE OF THIS, THERE IS A GREAT DEAL OF INTEREST IN USING NON-INVASIVE METHODS TO DIAGNOSE REJECTION IN HEART TRANSPLANT PATIENTS. THE STUDY AIMS TO DEMONSTRATE THAT ACUTE REJECTION OF THE TRANSPLANTED HEART CAN BE SAFELY MONITORED USING THIS BLOOD TEST, FIRST COMMERCIALLY INTRODUCED IN 2005, SO THAT REPEATED HEART BIOPSIES CAN BE AVOIDED. THIS BLOOD TEST, CALLED GENE EXPRESSION PROFILING (GEP), BRAND NAMED ALLOMAP, IDENTIFIES THE EXPRESSION OF GENES ON WHITE BLOOD CELLS THAT CIRCULATE IN THE BLOOD AND CAUSE THE HEART TO BE REJECTED.STUDY TITLE: CLINICAL TRIALS IN ORGAN TRANSPLANTATION (CTOT-11): NOVEL THERAPIES TO IMPROVE RENAL AND CARDIAC ALLOGRAFT OUTCOMESSPONSOR: NIHPROJECT SUMMARY: TRANSPLANTATION IS THE IDEAL THERAPY FOR END STAGE HEART AND END STAGE KIDNEY FAILURE, BUT ALLOGRAFT SURVIVAL AND FUNCTION REMAIN SUBOPTIMAL. THIS CTOT RENEWAL APPLICATION WILL BUILD UPON THE FINDINGS RESULTING FROM THE PREVIOUS 4 YEARS OF STUDYING BIOMARKERS AND MECHANISMS OF INJURY IN HEART AND KIDNEY TRANSPLANT RECIPIENTS IN AN EFFORT TO DEVELOP THERAPIES TAILORED TO INDIVIDUAL PATIENTS. THE OVERRIDING CLINICAL HYPOTHESIS IS THAT SPECIFICALLY DESIGNED THERAPIES GUIDED BY RATIONALLY CHOSEN NONINVASIVE IMMUNE MONITORING WILL IMPROVE OUTCOMES IN HEART AND KIDNEY TRANSPLANT RECIPIENTS. THE STUDY WILL INVOLVE IDENTIFYING HEART TRANSPLANT CANDIDATES AT HIGH RISK FOR ANTIBODY MEDIATED INJURY (HIGH PRA) AND PERFORMING A PILOT STUDY TO DETERMINE THE SAFETY AND EFFICACY OF DESENSITIZATION USING A COMBINATION OF B CELL DEPLETION (RITUXIMAB), IVIG PLASMAPHERESIS. THE STUDY WILL TEST THE HYPOTHESIS THAT DESENSITIZATION WILL LOWER PRA, DIMINISH THE WAITING TIME TO HEART TRANSPLANTATION AND RESULT IN ACCEPTABLE 1 YEAR GRAFT SURVIVAL AND FUNCTION. PATIENTS WILL BE ENROLLED FROM WITHIN A POWERFUL CONSORTIUM OF 22 NORTH AMERICAN HEART TRANSPLANT CENTERS THAT WAS DEVELOPED FOR THE ONGOING HEART TRANSPLANTATION CTOT05 STUDY. ASSOCIATED MECHANISTIC STUDIES WILL DETERMINE HOW THE DESENSITIZATION PROTOCOL IMPACTS PREFORMED ALLOREACTIVE T AND B CELL IMMUNITY AND WILL TEST THE HYPOTHESIS THAT RESIDUAL B AND T CELL IMMUNE MEMORY WITH REACTIVITY TO DONOR ANTIGENS MEDIATES POST-TRANSPLANT ALLOGRAFT INJURY.STUDY TITLE: RISK FACTORS AND OUTCOMES POST HEART TRANSPLANTATIONSPONSOR: INTERNALPROJECT SUMMARY: THE PURPOSE OF THIS CLINICAL RESEARCH IS TO RETROSPECTIVELY REVIEW DATA ON PATIENTS TRANSPLANTED AT CEDARS-SINAI MEDICAL CENTER TO ASSESS A VARIETY OF FACTORS AND THEIR IMPACT ON BOTH SHORT-TERM AND LONG-TERM SURVIVAL POST HEART TRANSPLANTATION. THE DATA THAT WILL BE COLLECTED AND ANALYZED WILL BE EXTRACTED FROM MEDICAL RECORDS, AND THIS DATA WILL CONSIST OF DEMOGRAPHICS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS. DEMOGRAPHICS WILL CONSIST OF BOTH RECIPIENT AND DONOR CHARACTERISTICS. OUTCOMES MAY CONSIST OF LABORATORY RESULTS, PROCEDURAL RESULTS, CLINICAL DIAGNOSES, HOSPITALIZATION INFORMATION, LIST OF MEDICATIONS, HOSPITALIZATIONS, LABORATORY RESULTS, AS WELL AS ANY OTHER ADDITIONAL RELEVANT DATA. WITH SUCH AN EXTENSIVE HEART TRANSPLANT PROGRAM WITH A LARGE COHORT OF PATIENTS, DATA FROM OUR RESEARCH WOULD GREATLY ENHANCE AND BENEFIT THE FIELD OF HEART TRANSPLANTATION. BY EVALUATING THE DATA OF ALL HEART TRANSPLANT PATIENTS IN ONE COMPREHENSIVE DATABASE STUDY, WE MAY BE ABLE TO IMPROVE OUR UNDERSTANDING OF HEART TRANSPLANTATION AS WELL AS THE QUALITY OF LIFE OF HEART TRANSPLANT PATIENTS.Description
Total Program Service Expense1103728TotalProgramServiceExpense
Described In501 C31DescribedIn501C3
Schedule B Required1ScheduleBRequired
Political Activities0PoliticalActivities
Lobbying Activities0LobbyingActivities
Subject To Proxy Tax0SubjectToProxyTax
Donor Advised Funds0DonorAdvisedFunds
Conservation Easements0ConservationEasements
Collections Of Art0CollectionsOfArt
Credit Counseling0CreditCounseling
Term Or Permanent Endowments0TermOrPermanentEndowments
Report Land Bldg Equip1ReportLandBldgEquip
Report Invest Oth Securities0ReportInvestOthSecurities
Report Prog Rel Invest0ReportProgRelInvest
Report Other Assets0ReportOtherAssets
Report Other Liabilities0ReportOtherLiabilities
Report Fin48 Footnote0ReportFin48Footnote
Independent Audit Financial Stmt0IndependentAuditFinancialStmt
Consolidated Audit Financial Stmt0ConsolidatedAuditFinancialStmt
School0School
Foreign Office0ForeignOffice
Foreign Activities0ForeignActivities
More Than5000 K To Organizations0MoreThan5000KToOrganizations
More Than5000 K To Individuals0MoreThan5000KToIndividuals
Professional Fundraising0ProfessionalFundraising
Fundraising Activities0FundraisingActivities
Gaming0Gaming
Hospital0Hospital
Grants To Organizations0GrantsToOrganizations
Grants To Individuals0GrantsToIndividuals
Schedule J Required1ScheduleJRequired
Tax Exempt Bonds0TaxExemptBonds
Excess Benefit Transaction0ExcessBenefitTransaction
Prior Excess Benefit Transaction0PriorExcessBenefitTransaction
Loan To Officer Or DQP0LoanToOfficerOrDQP
Grant To Related Person0GrantToRelatedPerson
Bsnss Rltnshp With Organization0BsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family Member0BsnssRltnshpThruFamilyMember
Officer Entity With Bsnss Rltnshp0OfficerEntityWithBsnssRltnshp
Deductible Non Cash Contributions0DeductibleNonCashContributions
Deductible Contributions Of Art0DeductibleContributionsOfArt
Terminated0Terminated
Partial Liquidation0PartialLiquidation
Disregarded Entity0DisregardedEntity
Related Entity1RelatedEntity
Related Org Controlled Entity1RelatedOrgControlledEntity
Transaction Related Entity0TransactionRelatedEntity
Transfers To Exempt Non Chrtbl Org0TransfersToExemptNonChrtblOrg
Activities Conducted Partnership0ActivitiesConductedPartnership
Schedule O Required1ScheduleORequired
Number Forms Transmitted With10965NumberFormsTransmittedWith1096
Number W2 G Included0NumberW2GIncluded
Compliance With Backup Witholding1ComplianceWithBackupWitholding
Number Of Employees0NumberOfEmployees
Unrelated Business Income0UnrelatedBusinessIncome
Foreign Financial Account0ForeignFinancialAccount
Prohibited Tax Shelter Trans0ProhibitedTaxShelterTrans
Taxable Party Notification0TaxablePartyNotification
Non Deductible Contributions0NonDeductibleContributions
Quid Pro Quo Contributions0QuidProQuoContributions
Form8282 Property Disposed Of0Form8282PropertyDisposedOf
Funds To Pay Premiums0FundsToPayPremiums
Premiums Paid0PremiumsPaid
Indoor Tanning Services0IndoorTanningServices
Info In Schedule O Part VIXInfoInScheduleOPartVI
Nbr Voting Governing Body Members18NbrVotingGoverningBodyMembers
Number Independent Voting Members13NumberIndependentVotingMembers
Family Or Business Relationship1FamilyOrBusinessRelationship
Delegation Of Management Duties0DelegationOfManagementDuties
Changes To Organizing Docs0ChangesToOrganizingDocs
Material Diversion Or Misuse0MaterialDiversionOrMisuse
Members Or Stockholders1MembersOrStockholders
Election Of Board Members1ElectionOfBoardMembers
Decisions Subject To Approval1DecisionsSubjectToApproval
Minutes Of Governing Body1MinutesOfGoverningBody
Minutes Of Committees1MinutesOfCommittees
Officer Mailing Address0OfficerMailingAddress
Local Chapters0LocalChapters
Form990 Provided To Governing Body0Form990ProvidedToGoverningBody
Conflict Of Interest Policy1ConflictOfInterestPolicy
Annual Disclosure Covered Persons1AnnualDisclosureCoveredPersons
Regular Monitoring Enforcement1RegularMonitoringEnforcement
Whistleblower Policy0WhistleblowerPolicy
Document Retention Policy0DocumentRetentionPolicy
Compensation Process CEO0CompensationProcessCEO
Compensation Process Other1CompensationProcessOther
Investment In Joint Venture0InvestmentInJointVenture
States Where Copy Of Return Is FiledCAStatesWhereCopyOfReturnIsFiled
Upon RequestXUponRequest

The Books Are In Care Of TheBooksAreInCareOf

Name Business NameBusiness

FieldValueIRS element (for citing)
Business Name Line1ERIC MARTONBusinessNameLine1
FieldValueIRS element (for citing)
Telephone Number3102488327TelephoneNumber

Address US AddressUS

FieldValueIRS element (for citing)
Address Line18536 WILSHIRE BOULEVARD 3RD FLOORAddressLine1
CityBEVERLY HILLSCity
StateCAState
ZIP Code90211ZIPCode
FieldValueIRS element (for citing)
Info In Schedule O Part VIIXInfoInScheduleOPartVII

Form990 Part VII Section A Form990PartVIISectionA (20 entries)

TitleTitleAverage Hours Per WeekAverageHoursPerWeekIndividual Trustee Or DirectorIndividualTrusteeOrDirectorOfficerOfficerReportable Comp From OrganizationReportableCompFromOrganizationReportable Comp From Related OrgsReportableCompFromRelatedOrgsOther CompensationOtherCompensation
JON KOBASHIGAWA MD
VOLUNTARY CHIEF MED OFCR2.00XX50000
KEENAN BEHRLE
CHAIRPERSON2.00XX000
JAMES HAMILTON
SECRETARY2.00XX000
KAY DILLARD
DIRECTOR2.00X000
THOMAS D GORDON
CFO1.00XX0892737215598
RUSSELL FAUCETT
DIRECTOR2.00X000
IRENE FURLONG
DIRECTOR2.00X000
MICHELE HAMILTON MD
DIRECTOR2.00X50000
RICHARD B JACOBS
DIRECTOR1.00X0892185238563
E ERIC JOHNSON
DIRECTOR2.00X000
JOSEPH O LAMPE
DIRECTOR2.00X000
EDUARDO MARBAN MD
DIRECTOR1.00X02003956206666
LAURENCE MARTON MD
DIRECTOR2.00X000
ARTHUR J OCHOA
DIRECTOR1.00X0106517956841
WILLIAM OUCHI PHD
DIRECTOR2.00X000
EDWARD PRUNCHUNAS
DIRECTOR1.00X01181611263882
LAWRENCE SOUZA PHD
DIRECTOR2.00X000
PHILLIP L WILLIAMS
DIRECTOR2.00X000
ERIC N MARTON
PRESIDENT30.00X032826342153
CHRISTINE SUMBI
VICE-PRESIDENT40.00X012803215201
FieldValueIRS element (for citing)
Total Reportable Comp From Org1000TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs6491963TotalReportableCompFrmRltdOrgs
Total Other Compensation1038904TotalOtherCompensation
Number Individuals GT100 K0NumberIndividualsGT100K
Formers Listed0FormersListed
Total Comp GT150 K1TotalCompGT150K
Compensation From Other Sources0CompensationFromOtherSources
Number Of Contractors GT100 K0NumberOfContractorsGT100K
Related Organizations1277550RelatedOrganizations
All Other Contributions3311AllOtherContributions
Total Contributions1280861TotalContributions

Program Service Revenue ProgramServiceRevenue

FieldValueIRS element (for citing)
DescriptionEDUCATIONAL PROGRAMSDescription
Business Code611430BusinessCode
Total Revenue Column29520TotalRevenueColumn
Related Or Exempt Function Income29520RelatedOrExemptFunctionIncome
FieldValueIRS element (for citing)
Total Program Service Revenue29520TotalProgramServiceRevenue

Investment Income InvestmentIncome

FieldValueIRS element (for citing)
Total Revenue Column18834TotalRevenueColumn
Exclusion$18,834ExclusionAmount

Gross Amount Sales Assets GrossAmountSalesAssets

FieldValueIRS element (for citing)
Securities197Securities

Gain Or Loss GainOrLoss

FieldValueIRS element (for citing)
Securities197Securities

Net Gain Or Loss Investments NetGainOrLossInvestments

FieldValueIRS element (for citing)
Total Revenue Column197TotalRevenueColumn
Exclusion$197ExclusionAmount

Total Revenue TotalRevenue

FieldValueIRS element (for citing)
Total Revenue Column1329412TotalRevenueColumn
Related Or Exempt Function Income29520RelatedOrExemptFunctionIncome
Unrelated Business Revenue0UnrelatedBusinessRevenue
Exclusion$19,031ExclusionAmount

Comp Current Officers Directors CompCurrentOfficersDirectors

FieldValueIRS element (for citing)
Total285343Total
Management And General285343ManagementAndGeneral

Other Salaries And Wages OtherSalariesAndWages

FieldValueIRS element (for citing)
Total701535Total
Program Services701535ProgramServices

Pension Plan Contributions PensionPlanContributions

FieldValueIRS element (for citing)
Total35471Total
Program Services35471ProgramServices

Other Employee Benefits OtherEmployeeBenefits

FieldValueIRS element (for citing)
Total17981Total
Program Services17981ProgramServices

Payroll Taxes PayrollTaxes

FieldValueIRS element (for citing)
Total72950Total
Program Services72950ProgramServices

Fees For Services Legal FeesForServicesLegal

FieldValueIRS element (for citing)
Total2400Total
Management And General2400ManagementAndGeneral

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

FieldValueIRS element (for citing)
Total3015Total
Management And General3015ManagementAndGeneral

Fees For Services Other FeesForServicesOther

FieldValueIRS element (for citing)
Total58904Total
Program Services33575ProgramServices
Management And General25329ManagementAndGeneral

Advertising Advertising

FieldValueIRS element (for citing)
Total1250Total
Management And General1250ManagementAndGeneral

Office Expenses OfficeExpenses

FieldValueIRS element (for citing)
Total18575Total
Program Services18192ProgramServices
Management And General383ManagementAndGeneral

Information Technology InformationTechnology

FieldValueIRS element (for citing)
Total7594Total
Program Services3797ProgramServices
Management And General3797ManagementAndGeneral

Occupancy Occupancy

FieldValueIRS element (for citing)
Total166438Total
Program Services166438ProgramServices

Travel Travel

FieldValueIRS element (for citing)
Total399Total
Program Services399ProgramServices

Conferences Meetings ConferencesMeetings

FieldValueIRS element (for citing)
Total107902Total
Management And General107902ManagementAndGeneral

Depreciation Depletion DepreciationDepletion

FieldValueIRS element (for citing)
Total43421Total
Program Services43421ProgramServices

Insurance Insurance

FieldValueIRS element (for citing)
Total7098Total
Program Services2625ProgramServices
Management And General4473ManagementAndGeneral

Other Expenses OtherExpenses (4 entries)

DescriptionDescriptionTotalTotalManagement And GeneralManagementAndGeneralProgram ServicesProgramServices
BANK/CREDIT CARD FEES46074607
STORAGE41984198
DUES & SUBSCRIPTIONS36164703146
LICENSES & TAXES16561656

All Other Expenses AllOtherExpenses

FieldValueIRS element (for citing)
Total27155Total
Management And General27155ManagementAndGeneral

Total Functional Expenses TotalFunctionalExpenses

FieldValueIRS element (for citing)
Total1571508Total
Program Services1103728ProgramServices
Management And General467780ManagementAndGeneral
Fundraising0Fundraising

Cash Non Interest Bearing CashNonInterestBearing

FieldValueIRS element (for citing)
BOY71431BOY
EOY66614EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

FieldValueIRS element (for citing)
BOY137417BOY
EOY14678EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

FieldValueIRS element (for citing)
BOY7098BOY
EOY4687EOY
FieldValueIRS element (for citing)
Land Buildings Equipment Basis461008LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec151030LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

FieldValueIRS element (for citing)
BOY353400BOY
EOY309978EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

FieldValueIRS element (for citing)
BOY641233BOY
EOY559744EOY

Investments Other Securities InvestmentsOtherSecurities

FieldValueIRS element (for citing)
BOY2550BOY
EOY0EOY

Other Assets Total OtherAssetsTotal

FieldValueIRS element (for citing)
BOY10561BOY
EOY10561EOY

Total Assets TotalAssets

FieldValueIRS element (for citing)
BOY1223690BOY
EOY966262EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

FieldValueIRS element (for citing)
BOY77487BOY
EOY81870EOY

Total Liabilities TotalLiabilities

FieldValueIRS element (for citing)
BOY77487BOY
EOY81870EOY
FieldValueIRS element (for citing)
Follow SFAS117XFollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

FieldValueIRS element (for citing)
BOY1146203BOY
EOY884392EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

FieldValueIRS element (for citing)
BOY1146203BOY
EOY884392EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

FieldValueIRS element (for citing)
BOY1223690BOY
EOY966262EOY
FieldValueIRS element (for citing)
Info In Schedule O Part XIXInfoInScheduleOPartXI
Reconcilation Revenue Expenses-242096ReconcilationRevenueExpenses
Reconcilation Other Changes-19715ReconcilationOtherChanges
Method Of Accounting AccrualXMethodOfAccountingAccrual
Accountant Compile Or Review0AccountantCompileOrReview
FS Audited0FSAudited
Federal Grant Audit Required0FederalGrantAuditRequired

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Publicly Supported Org170b1 AviXPubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years393819CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years1380752CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years1202798CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year2355777CurrentTaxYearMinus1Year
Current Tax Year1280861CurrentTaxYear
Total6614007Total

Total170 Total170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years393819CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years1380752CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years1202798CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year2355777CurrentTaxYearMinus1Year
Current Tax Year1280861CurrentTaxYear
Total6614007Total
FieldValueIRS element (for citing)
Amounts Subst Contributors Total2980277AmountsSubstContributorsTotal
Public Support Total1703633730PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years28302CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years11200CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years7427CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year12029CurrentTaxYearMinus1Year
Current Tax Year18834CurrentTaxYear
Total77792Total

Net UBI NetUBI

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years21443CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years25CurrentTaxYearMinus3Years
Total21468Total
FieldValueIRS element (for citing)
Total Support6713267TotalSupport
Gross Receipts From Admissions Etc244958GrossReceiptsFromAdmissionsEtc
Public Support Pertcentage1700.54130PublicSupportPertcentage170
Public Support Pertcent Prior Year0.41390PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170XThirtyThreePercntTestsCY170

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

FieldValueIRS element (for citing)
Contributor NumberRESTRICTEDContributorNumber

Contributor Name Business ContributorNameBusiness

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor Address US ContributorAddressUS

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Aggregate ContributionsRESTRICTEDAggregateContributions

Schedule D IRS990ScheduleD

Buildings Buildings

FieldValueIRS element (for citing)
Other Cost Or Other Basis346762OtherCostOrOtherBasis
Depreciation80920Depreciation
Book Value265842BookValue

Equipment Equipment

FieldValueIRS element (for citing)
Other Cost Or Other Basis77162OtherCostOrOtherBasis
Depreciation51567Depreciation
Book Value25595BookValue

Other Land Buildings OtherLandBuildings

FieldValueIRS element (for citing)
Other Cost Or Other Basis37084OtherCostOrOtherBasis
Depreciation18543Depreciation
Book Value18541BookValue
FieldValueIRS element (for citing)
Total Of Book Value Land Buildings309978TotalOfBookValueLandBuildings

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Severance Payment0SeverancePayment
Supplemental Nonqual Retire Plan1SupplementalNonqualRetirePlan
Equity Based Comp Arrangement0EquityBasedCompArrangement
Comp Based On Revenue Of Filing Org0CompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related Orgs0CompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing Org0CompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate Orgs0CompBasedNetEarningsRelateOrgs
Any Non Fixed Payments0AnyNonFixedPayments
Initial Contract Exception0InitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (6 entries)

Base Compensation Filing OrgBaseCompensationFilingOrgComp Based On Related OrgsCompBasedOnRelatedOrgsBonus Filing OrgBonusFilingOrgBonus Related OrgsBonusRelatedOrgsOther Compensation Filing OrgOtherCompensationFilingOrgOther Compensation Related OrgsOtherCompensationRelatedOrgsDeferred Comp Filing OrgDeferredCompFilingOrgDeferred Comp Related OrgsDeferredCompRelatedOrgsNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgNontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgsTotal Compensation Filing OrgTotalCompensationFilingOrgTotal Compensation Related OrgsTotalCompensationRelatedOrgsComp Report Prior990 Filing OrgCompReportPrior990FilingOrgComp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs
THOMAS D GORDON
04646240224848020326501863860292120110833500
RICHARD B JACOBS
05022580239025015090202218190167440113074800
EDUARDO MARBAN MD
011664970238469059899001647650419010221062200
ARTHUR J OCHOA
040062405926860718690209450358960112202000
EDWARD PRUNCHUNAS
06022620282153029719602240420398400144549300
ERIC N MARTON
0273831035500018932014765027388037041600

Form990 Schedule J Part III Form990ScheduleJPartIII (2 entries)

Return ReferenceReturnReferenceExplanationExplanationIdentifierIdentifier
PART I, LINE 4BTHE PLAN IS A SUPPLEMENTAL RETIREMENT ALLOWANCE THAT IS PAYABLE DIRECTLY TO THE PARTICIPANTS EACH QUARTER. THE BENEFIT FORMULA FOR THIS PLAN HAS ANNUAL CONTRIBUTIONS THAT ARE EITHER A PERCENTAGE OF SALARY, OR ARE DESIGNED TO FUND A PERCENTAGE OF THE ESTIMATED FINAL 5-YEAR AVERAGE SALARY. ONE INDIVIDUAL ALSO RECEIVED PAYOUT FROM AMOUNTS ACCRUED IN A PRIOR YEAR. THE FOLLOWING OFFICERS, DIRECTORS, KEY EMPLOYEES AND HIGHEST-COMPENSATED EMPLOYEES RECEIVED PAYMENTS DURING THE YEAR ENDED DECEMBER 31, 2011. THOMAS D. GORDON 177,961 RICHARD B. JACOBS 133,742 EDUARDO MARBAN, MD 509,443 ERIC N. MARTON 17,080 ARTHUR J. OCHOA 68,048 EDWARD PRUNCHUNAS 239,222
PART IIISCHEDULE J, PART I, LINE 3: THE PRESIDENT IS COMPENSATED BY A RELATED ORGANIZATION. PLEASE SEE SCHEDULE O NARRATIVE FOR PART VI, LINE 15.SUPPLEMENTAL INFORMATION

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (12 entries)

IdentifierIdentifierReturn ReferenceReturnReferenceExplanationExplanation
PROGRAM SERVICE STATEMENTSTUDY TITLE: HEARTSBREATH TEST FOR HEART TRANSPLANT REJECTIONSPONSOR: MENSANNA RESEARCH PROJECT SUMMARY: THIS RESEARCH WILL EVALUATE WHETHER THE HEARTSBREATH DEVICE CAN ASSIST IN DIAGNOSING HEART TRANSPLANT REJECTION IN PATIENTS WHO'VE RECEIVED A HEART TRANSPLANT DURING THE PRECEDING 12 MONTHS AND ARE ABOUT TO RECEIVE AN ENDOMYOCARDIAL BIOPSY. THE MAIN AIM OF THIS STUDY IS TO VALIDATE THE ACCURACY OF THE DEVICE TO DETECT HEART TRANSPLANT REJECTION, BY COLLECTING SAMPLES PRIOR TO BIOPSY AND COMPARING THEM WITH THE BIOPSY RESULTS. PATIENTS WHO HAVE RECEIVED A HEART TRANSPLANT WITHIN THE PREVIOUS 12 MONTHS AND ARE SCHEDULED FOR A ROUTINE ENDOMYOCARDIAL BIOPSY MAY BE ELIGIBLE FOR PARTICIPATION IN THIS TRIAL. RIGHT VENTRICULAR ENDOMYOCARDIAL BIOPSY IS CURRENTLY THE "GOLD STANDARD" FOR DIAGNOSIS OF HEART TRANSPLANT REJECTION. ALTHOUGH CONSIDERED SAFE, THE PROCEDURE IS INVASIVE AND MAY CAUSE COMPLICATIONS. ALSO, THERE ARE DISCREPANCIES BETWEEN BIOPSY READINGS WITH REGARD TO GRADING OF REJECTIONS SUFFICIENT TO HAVE ADVERSE TREATMENT IMPLICATIONS. SEVERAL NON-INVASIVE TESTS FOR HEART TRANSPLANT REJECTION HAVE BEEN PROPOSED, HOWEVER, THEIR ACCURACY IS GENERALLY TOO POOR TO GUIDE CLINICAL DECISION MAKING IN INDIVIDUAL PATIENTS. THE BREATH TESTS USES BIOMARKERS FOUND IN HUMAN BREATH AS INDICATORS FOR REJECTION AND ITS INTENSITY. A SCREENING BREATH TEST COULD POTENTIALLY IDENTIFY TRANSPLANT RECIPIENTS AT LOW RISK OF GRADE 3 REJECTION AND REDUCE THE NUMBER OF ENDOMYOCARDIAL BIOPSIES. STUDY TITLE: ACE INHIBITION AND CARDIAC ALLOGRAFT VASCULOPATHY SPONSOR: NIH/STANFORD UNIVERSITY PROJECT SUMMARY: THE PURPOSE OF THIS STUDY IS TO INVESTIGATE THE EFFECT OF THE ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE I), RAMIPRIL, AN ANTIHYPERTENSIVE AGENT, ON THE DEVELOPMENT OF CARDIAC ALLOGRAFT VASCULOPATHY (CAV) IN CARDIAC TRANSPLANT RECIPIENTS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. CARDIAC ALLOGRAFT VASCULOPATHY (CAV) IS A LEADING CAUSE OF MORBIDITY AND MORTALITY AFTER HEART TRANSPLANT. DESPITE ADVANCES IN PROPHYLAXIS AGAINST REJECTION AND INFECTION, AS WELL AS IMPROVED CONTROL OF TRADITIONAL ATHEROSCLEROTIC RISK FACTORS, SIGNIFICANT DEVELOPMENT OF ATHEROSCLEROTIC PLAQUE AND DETRIMENTAL VASCULAR REMODELING OCCUR EARLY AFTER ORTHOTOPIC HEART TRANSPLANTATION (OHT). THE INVESTIGATORS HOPE TO DETERMINE WHETHER ACE I THERAPY WITH RAMIPRIL EARLY AFTER OHT IMPACTS THE DEVELOPMENT OF CAV, AND LEARN IF THE USE OF ACE I INCREASES THE NUMBER OF CIRCULATING ENDOTHELIAL PROGENITOR CELLS (EPC) RESULTING IN IMPROVED ENDOTHELIAL FUNCTION AND LESS ATHEROSCLEROSIS. THE PRIMARY OBJECTIVE IS TO INVESTIGATE THE EFFECT OF ACE I ON THE DEVELOPMENT OF CAV IN CARDIAC TRANSPLANT RECIPIENTS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. STUDY TITLE: EXTERNAL FACTORS AND OUTCOMES FOR HEART TRANSPLANT RECIPIENTS: A SINGLE CENTER SURVEY STUDY SPONSOR: INTERNAL PROJECT SUMMARY: CARDIAC TRANSPLANTATION IS CURRENTLY THE PROCEDURE OF CHOICE FOR SELECTED PATIENTS WITH END-STAGE HEART DISEASE THAT IS NOT AMENABLE TO FURTHER MEDICAL INTERVENTION OR CONVENTIONAL CARDIAC PROCEDURES. WITH THE ADVENT OF MORE EFFECTIVE IMMUNOSUPPRESSIVE AGENTS, THE DEFINITION OF THE SUCCESSFULLY MANAGED HEART TRANSPLANT RECIPIENT IS EVOLVING BEYOND THE IMMEDIATE CHALLENGE OF PREVENTING ACUTE REJECTION. THE PURPOSE OF THIS SURVEY STUDY IS TO ASSESS A VARIETY OF FACTORS AND THEIR IMPACT ON BOTH SHORT-TERM AND LONG-TERM OUTCOMES AND QUALITY OF LIFE POST HEART TRANSPLANTATION. A SURVEY INSTRUMENT TO OBTAIN POST HEART TRANSPLANT OUTCOMES DATA ON ABOUT 1,000 PATIENTS WILL BE EMPLOYED. DATA TO BE COLLECTED WILL INCLUDE DEMOGRAPHIC DATA, PSYCHOSOCIAL DATA AND PHYSICAL DATA. STUDY TITLE: PROSPECTIVE, MULTI-CENTER, RANDOMIZED CLINICAL INVESTIGATION OF TRANSMEDICS ORGAN CARE SYSTEM (OCS) FOR CARDIAC USE SPONSOR: TRANSMEDICS, INC. PROJECT SUMMARY: THE TRANSMEDICS ORGAN CARE SYSTEM IS A PORTABLE ORGAN PERFUSION AND MONITORING SYSTEM INTENDED TO PRESERVE A DONATED HEART IN A BEATING STATE DURING TRANSPORT FOR THE EVENTUAL TRANSPLANTATION INTO A RECIPIENT. THE ORGAN CARE SYSTEM (OCS) MAINTAINS ORGAN VIABILITY BY PROVIDING A CONTROLLED ENVIRONMENT, CONTINUOUSLY PERFUSING THE DONATED HEART WITH WARM, OXYGENATED BLOOD, SUPPLEMENTED WITH THE TRANSMEDICS CARDIAC SOLUTION SET. THE BLOOD IS COLLECTED FROM THE DONOR AND IS CONTINUOUSLY CIRCULATED TO THE ORGAN IN A CLOSED CIRCUIT ALONG WITH THE CARDIAC SOLUTION SET. THE OCS PRESERVES THE HEART AND MONITORS THE ORGAN'S PERFUSION PARAMETERS IMMEDIATELY AFTER EXPLANTATION FROM A DONOR AND CONNECTION TO THE DEVICE, DURING TRANSPORTATION TO THE RECIPIENT SITE, AND UNTIL DISCONNECTION FROM THE DEVICE. THE PURPOSE OF THIS STUDY IS TO COMPARE THE SAFETY AND EFFECTIVENESS OF THE OCS WITH THE EXISTING COLD STATIC CARDIOPLEGIA STANDARD OF CARE FOR THE PRESERVATION OF DONOR HEARTS. STUDY TITLE: A POSTMARKETING OBSERVATIONAL STUDY TO ASSESS RESPIRATORY TRACT ADVERSE EVENTS IN PULMONARY ARTERIAL HYPERTENSION PATIENTS WITH TYVASO(R) (TREPROSTINIL) INHALATION SOLUTION SPONSOR: UNITED THERAPEUTICS PROJECT SUMMARY: TYVASO(R) (TREPROSTINIL) IS AN INHALED PROSTACYCLIN VASODILATOR RECENTLY APPROVED IN THE US FOR GROUP 1 PULMONARY ARTERIAL HYPERTENSION PATIENTS. DURING THE APPROVAL PROCESS, THE FDA EXPRESSED CONCERNS THAT TREPROSTINIL MAY BE IRRITATING TO THE RESPIRATORY TRACT WHEN ADMINISTERED BY THE INHALATION ROUTE. THUS, A POST MARKETING REQUIREMENT HAS BEEN MANDATED, SPECIFICALLY A LONG-TERM OBSERVATIONAL STUDY TO FURTHER EVALUATE THE POTENTIAL ASSOCIATION BETWEEN TREPROSTINIL AND ORO-/NASOPHARYNGEAL AND PULMONARY ADVERSE EVENTS. THIS STUDY WILL BE A LONG-TERM OBSERVATIONAL STUDY IN THE US THAT WILL INCLUDE 1000 PATIENT-YEARS OF MONITORING IN TYVASO-TREATED PATIENTS, AND 1000 PATIENT-YEARS OF FOLLOW-UP IN MATCHED CONTROLS RECEIVING OTHER FDA APPROVED TREATMENTS FOR PULMONARY HYPERTENSION. THE PRIMARY OBJECTIVE OF THE STUDY IS TO DESCRIBE THE TYPE AND INCIDENCE OF ORO-/NASOPHARYNGEAL AND PULMONARY ADVERSE EVENTS THAT MAY BE ASSOCIATED WITH CURRENT OR RECENT TREATMENT WITH TYVASO FOR PAH. THE SECONDARY OBJECTIVE OF THE STUDY IS TO COMPARE THE INCIDENCE OF SELECTED ORO-/NASOPHARYNGEAL AND PULMONARY ADVERSE EVENTS IN PATIENTS TREATED WITH TYVASO FOR PAH WITH PATIENTS NOT TREATED WITH TYVASO FOR PAH.
FORM 990, PART IV, LINE 12THE ORGANIZATION WAS INCLUDED IN A CONSOLIDATED, INDEPENDENT AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEARS ENDED 6/30/11 AND 6/30/12 DUE TO THE FACT THAT THE TAX YEAR OF ITS TAX-EXEMPT PARENT ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, ENDS ON 6/30. THERE ARE NO AUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 12/31/11.
FORM 990, PART VI, SECTION A, LINE 2LAURENCE MARTON, MD, DIRECTOR AND ERIC MARTON, PRESIDENT HAVE A FAMILY RELATIONSHIP.
FORM 990, PART VI, SECTION A, LINE 6CEDARS-SINAI MEDICAL CENTER IS THE SOLE CORPORATE MEMBER OF CALIFORNIA HEART CENTER FOUNDATION.
FORM 990, PART VI, SECTION A, LINE 7ACEDARS-SINAI MEDICAL CENTER AS THE SOLE CORPORATE MEMBER, CAN ELECT BOARD OF DIRECTORS TO CALIFORNIA HEART CENTER FOUNDATION.
FORM 990, PART VI, SECTION A, LINE 7BRESERVED RIGHTS OF CEDARS-SINAI MEDICAL CENTER, THE SOLE CORPORATE MEMBER OF THE ORGANIZATION. THE FOLLOWING ACTIONS MUST BE APPROVED OR ACTED UPON BY CEDARS-SINAI MEDICAL CENTER BEFORE BECOMING EFFECTIVE: (A) ANY SALE OR OTHER DISPOSITION OF ALL OR A SUBSTANTIAL PORTION OF THE ASSETS OF THE ORGANIZATION; (B) ANY MERGER OR AFFILIATION OF THE ORGANIZATION WITH ANY PERSON OR ENTITY OTHER THAN THE MEMBER; (C) ANY AMENDMENT TO THE ARTICLES OF INCORPORATION OR BYLAWS OF THE ORGANIZATION; (D) ANY ACT OR OMISSION WHICH CREATES ANY MATERIAL RISK TO THE MEMBER'S TAX EXEMPT STATUS, OR CREATES ANY MATERIAL RISK OF A VIOLATION OF ANY STATE OR FEDERAL LAWS; (E) DISSOLUTION OF THE ORGANIZATION OR THE FILING OF ANY BANKRUPTCY PETITION; (F) CREATION OF ANY NEW CORPORATION, PARTNERSHIP OR ASSOCIATION; (G) ACQUISITION OF OR THE INVESTMENT IN A NEW OPERATING BUSINESS; (H) ENTERING INTO ANY PARTNERSHIPS OR JOINT VENTURES; (I) ADOPTION OF OR CHANGES TO OPERATING OR CAPITAL BUDGETS; (J) ADOPTION OF THIS CORPORATION'S POLICIES AND PROCEDURES; (K) EXECUTION AND DELIVERY OF ANY NEW AFFILIATION AGREEMENTS AND OTHER RELATIONSHIPS WITH THE UCLA SCHOOL OF MEDICINE AND OTHER INSTITUTIONS OF MEDICAL LEARNING; (L) UNBUDGETED CAPITAL EXPENDITURES OVER $100,000; (M) LOANS, BORROWINGS OR GUARANTEES IN EXCESS OF $100,000, UNLESS APPROVED IN THE BUDGET; (N) ANY SECURITY INTERESTS OR MORTGAGES ON THE PROPERTY OF ORGANIZATION; (O) OPERATING OR CAPITAL LEASES WHERE THE TERM IS OVER FIVE YEARS OR THE TOTAL OBLIGATION UNDER THE LEASE EXCEEDS $100,000, UNLESS APPROVED IN THE BUDGET; (P) TERMINATION OR SELECTION OF THE AUDITORS OF THE ORGANIZATION; (Q) SUBJECT TO SECTION 5.08, APPOINTMENT OR REMOVAL OF ANY MEMBER OF THE BOARD (OTHER THAN EX-OFFICIO DIRECTORS); (R) APPOINTMENT OF REMOVAL OF ANY OFFICERS; (S) EXECUTION AND DELIVERY OF ANY PROFESSIONAL SERVICE AGREEMENTS; (T) RELOCATION OF PRINCIPAL OFFICE; (U) FIXING THE NUMBER OF DIRECTORS OF THE ORGANIZATION
FORM 990, PART VI, SECTION B, LINE 11THE ORGANIZATION'S FORM 990 UNDERGOES AN INTENSE AND HIGHLY COMPREHENSIVE REVIEW PROCESS. THE REVIEW INVOLVES VARIOUS MANAGEMENT PERSONNEL AND A BIG FOUR ACCOUNTING FIRM.
FORM 990, PART VI, SECTION B, LINE 12CCONFLICT OF INTEREST POLICY ANNUAL STATEMENTS: EACH DIRECTOR, OFFICER, MEMBER OF A COMMITTEE WITH BOARD-DELEGATED POWERS AND ANY OTHER INTERESTED PERSON AS DETERMINED BY THE BOARD OR COMMITTEE SHALL AT LEAST ANNUALLY SIGN A COPY OF THE "STATEMENT PERTAINING TO CONFLICT OF INTEREST." IF A DIRECTOR, OFFICER, OR COMMITTEE MEMBER, OR DESIGNATED INTERESTED PERSON BECOMES AWARE THAT A POTENTIAL OR APPARENT CONFLICT MAY EXIST WHICH IS NOT DISCLOSED ON SUCH A STATEMENT, IT SHALL BE THE RESPONSIBILITY OF THE INTERESTED PERSON TO DISCLOSE THE POTENTIAL CONFLICT TO THE PRESIDENT AND TO THE BOARD OR APPROPRIATE COMMITTEE AND AS SET FORTH ABOVE, PRIOR TO ANY BOARD OR COMMITTEE DISCUSSIONS OR ACTION WITH RESPECT TO THE RELEVANT TRANSACTION OR ARRANGEMENT, AND, IF RELEVANT, TO LEAVE THE MEETING DURING THE DISCUSSION AND VOTE ON THE TRANSACTION OR ARRANGEMENT. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE RELEVANT CALIFORNIA HEART CENTER FOUNDATION ("CHCF") OFFICER OR ADMINISTRATOR SHALL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS. IF IT IS DETERMINED THAT A CONFLICT OF INTEREST EXISTS AND, NOTWITHSTANDING THE CONFLICT, THE CHCF OFFICER OR ADMINISTRATOR DETERMINES THAT IT CONTINUES TO BE IN THE BEST INTERESTS OF CHCF TO PROCEED WITH THE TRANSACTION OR ARRANGEMENT AT ISSUE, THE CHCF OFFICER OR ADMINISTRATOR SHALL REFER THE TRANSACTION OR ARRANGEMENT TO THE BOARD OR THE APPROPRIATE BOARD-DESIGNATED COMMITTEE FOR EVALUATION. ALTERNATIVELY IF CONSIDERATION OF THE TRANSACTION OR ARRANGEMENT AT ISSUE IS A MATTER WITHIN THE SCOPE OF THE AUTHORITY OF THE BOARD OF DIRECTORS OR A COMMITTEE, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF THE EXISTENCE OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR COMMITTEE MEMBERS SHALL DECIDE, BY MAJORITY VOTE, IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. AN INTERESTED PERSON MAY MAKE A PRESENTATION TO THE BOARD OR COMMITTEE REGARDING THE TRANSACTION OR ARRANGEMENT. AFTER SUCH PRESENTATION THE INTERESTED PERSON MUST LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT. B. THE CHAIR OF THE BOARD OR COMMITTEE SHALL, IF DEEMED APPROPRIATE BY THE BOARD OR COMMITTEE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER CHCF CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN CHCF' BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO CHCF AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. VIOLATIONS OF THE CONFLICTS POLICY: A. IF THE BOARD OR COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A MEMBER OF THE BOARD OR COMMITTEE OR AN OFFICER OR OTHER INTERESTED PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OR OFFICER OR INTERESTED PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF SUCH PERSON AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION.
FORM 990, PART VI, SECTION B, LINE 15BTHE EXECUTIVE PERSONNEL COMMITTEE (THE COMMITTEE) OF THE TAX-EXEMPT PARENT OF THE ORGANIZATION, CEDARS-SINAI MEDICAL CENTER, IS A STANDING COMMITTEE OF THE BOARD OF DIRECTORS. THE COMMITTEE ADDRESSES COMPENSATION AND BENEFITS REGARDING THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER, AND IS AUTHORIZED BY THE BOARD OF DIRECTORS TO ACT ON BEHALF OF THE BOARD WITH RESPECT TO SUCH ISSUES, AND OTHER GOVERNANCE ISSUES AS REQUESTED BY THE BOARD OF DIRECTORS, THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS, THE CHAIR OF THE BOARD OF DIRECTORS, OR THE CEO, ALL SUBJECT TO THE COMMITTEE'S ONGOING REPORTING OBLIGATION TO THE BOARD OF DIRECTORS OR THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS. SPECIFICALLY, THE COMMITTEE EVALUATES THE PERFORMANCE AND APPROVES THE COMPENSATION AND BENEFITS FOR THE ORGANIZATION'S CHIEF FINANCIAL OFFICER AND BOARD MEMBERS WHO ARE ALSO EXECUTIVE EMPLOYEES AND CONTRACTUALLY ENGAGED FACULTY OF THE MEDICAL CENTER. THE MEMBERS OF THE COMMITTEE ARE APPOINTED ANNUALLY BY THE CHAIR OF THE MEDICAL CENTER'S BOARD OF DIRECTORS. APPOINTMENTS ARE FOR A ONE YEAR TERM. EACH YEAR, THE COMMITTEE FOLLOWS A PROCESS THAT ENSURES THAT THE COMPENSATION AND BENEFITS IS REASONABLE AND IN COMPLIANCE WITH APPLICABLE LAWS AND REGULATIONS. THE MEDICAL CENTER'S SVP OF HR PROVIDES STAFF SUPPORT TO THE COMMITTEE. THE COMMITTEE MAY INCLUDE MEMBERS OF THE MEDICAL CENTER'S MANAGEMENT TEAM OR ANY OTHER PERSON WHOSE PRESENCE THE COMMITTEE BELIEVES TO BE DESIRABLE OR APPROPRIATE. THE COMMITTEE MAY ENGAGE AN INDEPENDENT COMPENSATION AND BENEFITS CONSULTANT AND ANY OTHER ADVISORS THEY DEEM NECESSARY. THE COMMITTEE MAY ALSO ENGAGE INDEPENDENT COUNSEL. THE MEDICAL CENTER WILL PROVIDE FOR APPROPRIATE FUNDING FOR PAYMENT OF COSTS TO ANY SUCH PERSONS RETAINED BY THE COMMITTEE. ANNUALLY, AT THE COMMITTEE'S DIRECTION, THE INDEPENDENT COMPENSATION CONSULTANT SHALL PREPARE SUCH REPORTS AS THE COMMITTEE REASONABLY DEEMS NECESSARY. AT A MINIMUM, SUCH REPORTS WILL INCLUDE MARKET SURVEY DATA FROM A PEER GROUP DESIGNATED BY THE COMMITTEE, WHICH SHALL BE CONSIDERED BY THE COMMITTEE PRIOR TO MAKING DECISIONS. THE COMMITTEE MEETS AS FREQUENTLY AS THE COMMITTEE DEEMS NECESSARY AND WILL MAINTAIN WRITTEN MINUTES OF ITS MEETING. THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND VICE-PRESIDENT ARE DETERMINED BY THE CHIEF FINANCIAL OFFICER OF THE ORGANIZATION WITH ASSISTANCE FROM HR WHICH PROVIDES AN INDEPENDENT REVIEW OF COMPARABLES.
FORM 990, PART VI, SECTION C, LINE 19THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS AND ITS TAX-EXEMPT PARENT'S AUDITED FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON WRITTEN REQUEST.
FORM 990 PART VII - AVERAGE HOURS PER WEEK DEVOTED TO RELATED ORGANIZATIONSTHOMAS D. GORDON 65 HOURS RICHARD B. JACOBS 61 HOURS EDUARDO MARBAN, MD 60 HOURS ARTHUR J. OCHOA 65 HOURS EDWARD PRUNCHUNAS 65 HOURS ERIC N. MARTON 30 HOURS
CHANGES IN NET ASSETS OR FUND BALANCES:FORM 990, PART XI, LINE 5:NET UNREALIZED LOSSES ON INVESTMENTS: -19,715.

Schedule R IRS990ScheduleR

Form990 Schedule R Part II Form990ScheduleRPartII (3 entries)

Address Line1AddressUS/AddressLine1CityAddressUS/CityStateAddressUS/StateZIP CodeAddressUS/ZIPCodeEINEINPrimary ActivitiesPrimaryActivitiesLegal Domicile StateLegalDomicileStateExempt Code SectionExemptCodeSectionPublic Charity StatusPublicCharityStatusDirect Controlling Entity NADirectControllingEntityNAControlled OrgControlledOrgBusiness Name Line1DirectControllingEntityName/BusinessNameLine1
CEDARS-SINAI MEDICAL CENTER
8700 BEVERLY BOULEVARDLOS ANGELESCA90048951644600HEALTHCARECA501(C)(3)LINE 3N/A0
CEDARS-SINAI MEDICAL CARE FOUNDATION
200 N ROBERTSON BOULEVARD 101BEVERLY HILLSCA90211954457756PROVISION OF MEDICAL CARE, TEACHING AND RESEARCHCA501(C)(3)LINE 11A, I1CEDARS-SINAI MEDICAL CENTER
(no name)
1

Form990 Schedule R Part IV Form990ScheduleRPartIV (2 entries)

Address Line1AddressUS/AddressLine1CityAddressUS/CityStateAddressUS/StateZIP CodeAddressUS/ZIPCodeEINEINPrimary ActivityPrimaryActivityLegal Domicile StateLegalDomicileStateDirect Controlling Entity NADirectControllingEntityNAType Of EntityTypeOfEntity
GREATER VALLEY MANAGEMENT SERVICES ORGANIZATION INC
6500 WILSHIRE BLVD 8TH FLOORLOS ANGELESCA90048954439758MANAGEMENT FUNCTIONSCAN/AC
OPTIMATRIX HEALTH SOLUTIONS INC
6500 WILSHIRE BLVD 9TH FLOORLOS ANGELESCA90048954522779INFORMATION SYSTEMSCAN/AC
FieldValueIRS element (for citing)
Receipt Of Int Ann Rents Royalties0ReceiptOfIntAnnRentsRoyalties
Gift Grant Or Cap Contr To Other Org0GiftGrantOrCapContrToOtherOrg
Gift Grant Or Cap Contr Fr Other Org1GiftGrantOrCapContrFrOtherOrg
Loans Or Guarantees To Other Org0LoansOrGuaranteesToOtherOrg
Loans Or Guarantees From Other Org0LoansOrGuaranteesFromOtherOrg
Sale Of Assets To Other Org0SaleOfAssetsToOtherOrg
Purchase Of Assets From Other Org0PurchaseOfAssetsFromOtherOrg
Exchange Of Assets0ExchangeOfAssets
Rental Of Facilities To Other Orgs0RentalOfFacilitiesToOtherOrgs
Rental Of Facilities Fr Other Orgs0RentalOfFacilitiesFrOtherOrgs
Perform Of Services For Other Orgs0PerformOfServicesForOtherOrgs
Perform Of Services By Other Orgs0PerformOfServicesByOtherOrgs
Sharing Of Facilities0SharingOfFacilities
Sharing Of Paid Employees1SharingOfPaidEmployees
Reimbursement Paid To Other Org1ReimbursementPaidToOtherOrg
Reimbursement Paid By Other Org0ReimbursementPaidByOtherOrg
Other Transfer To Other Org0OtherTransferToOtherOrg
Other Transfer From Other Org0OtherTransferFromOtherOrg

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.